Elig.phs001124.v1.p1.1
Item
*CASES*
boolean
C1706256 (UMLS CUI [1,1])
Elig.phs001124.v1.p1.2
Item
Inclusion:
boolean
C1512693 (UMLS CUI [1,1])
Elig.phs001124.v1.p1.3
Item
Administration of TMP-SMX for at least 5 days prior to the adverse event
boolean
C1533734 (UMLS CUI [1,1])
C0041044 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C0877248 (UMLS CUI [1,5])
Elig.phs001124.v1.p1.4
Item
Documentation of one or more new clinical signs after starting TMP-SMX, including fever with or without eosinophilia, skin rash, increases in liver enzyme activities, hyperbilirubinemia, blood dyscrasias (anemia, leukopenia or thrombocytopenia), pneumonitis, myocarditis, aseptic meningitis, polyarthritis, acute interstitial nephritis, toxic epidermal necrolysis, or Stevens-Johnson syndrome
boolean
C0920316 (UMLS CUI [1,1])
C0205314 (UMLS CUI [1,2])
C0037088 (UMLS CUI [1,3])
C0332282 (UMLS CUI [1,4])
C0041044 (UMLS CUI [1,5])
C0015967 (UMLS CUI [1,6])
C2240374 (UMLS CUI [1,7])
C0015230 (UMLS CUI [1,8])
C0857093 (UMLS CUI [1,9])
C0020433 (UMLS CUI [1,10])
C0018939 (UMLS CUI [1,11])
C0002871 (UMLS CUI [1,12])
C0023530 (UMLS CUI [1,13])
C0040034 (UMLS CUI [1,14])
C3714636 (UMLS CUI [1,15])
C0027059 (UMLS CUI [1,16])
C0025290 (UMLS CUI [1,17])
C0162323 (UMLS CUI [1,18])
C1843274 (UMLS CUI [1,19])
C0014518 (UMLS CUI [1,20])
C0038325 (UMLS CUI [1,21])
Elig.phs001124.v1.p1.5
Item
Lack of other clinical explanation for the adverse event
boolean
C0332197 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205210 (UMLS CUI [1,3])
C0681841 (UMLS CUI [1,4])
C0877248 (UMLS CUI [1,5])
Elig.phs001124.v1.p1.6
Item
Resolution of clinical signs with discontinuation of TMP-SMX alone
boolean
C2699488 (UMLS CUI [1,1])
C0205210 (UMLS CUI [1,2])
C0037088 (UMLS CUI [1,3])
C0457454 (UMLS CUI [1,4])
C0041044 (UMLS CUI [1,5])
Elig.phs001124.v1.p1.7
Item
Exclusion:
boolean
C0680251 (UMLS CUI [1,1])
Elig.phs001124.v1.p1.8
Item
Gastrointestinal symptoms such as nausea, vomiting or diarrhea, in absence of other symptoms described above
boolean
C0426576 (UMLS CUI [1,1])
C0027497 (UMLS CUI [1,2])
C0042963 (UMLS CUI [1,3])
C0011991 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C1457887 (UMLS CUI [2,3])
C0678257 (UMLS CUI [2,4])
Elig.phs001124.v1.p1.9
Item
Acute anaphylactoid reactions were excluded
boolean
C0680251 (UMLS CUI [1,1])
C0001314 (UMLS CUI [1,2])
C0340865 (UMLS CUI [1,3])
Elig.phs001124.v1.p1.10
Item
Immunocompromised patients, including those with HIV infection or undergoing immunosuppressive chemotherapy
boolean
C4048329 (UMLS CUI [1,1])
C0019693 (UMLS CUI [1,2])
C0521116 (UMLS CUI [1,3])
C0021081 (UMLS CUI [1,4])
C0392920 (UMLS CUI [1,5])
Elig.phs001124.v1.p1.11
Item
*CONTROLS*
boolean
C0009932 (UMLS CUI [1,1])
Elig.phs001124.v1.p1.12
Item
Inclusion:
boolean
C1512693 (UMLS CUI [1,1])
Elig.phs001124.v1.p1.13
Item
Administration of a course of TMP-SMX at a standard therapeutic daily dosage for at least 10 days, with adequate follow-up in the medical record to indicate that the drug was taken and tolerated without adverse event.
boolean
C1533734 (UMLS CUI [1,1])
C1442989 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
C0041044 (UMLS CUI [1,5])
C0449238 (UMLS CUI [1,6])
C0205411 (UMLS CUI [1,7])
C1522577 (UMLS CUI [1,8])
C0025102 (UMLS CUI [1,9])
C1512806 (UMLS CUI [1,10])
C0013227 (UMLS CUI [1,11])
C0013220 (UMLS CUI [1,12])
C0332288 (UMLS CUI [1,13])
C0877248 (UMLS CUI [1,14])